Anticuerpos biespecíficos: nuevas terapias para prolongar la supervivencia y mejorar la calidad de vida de los pacientes con mieloma múltiple Published on 02/09/2024 La incidencia de esta enfermedad de la médula ósea supone el 10% de las neoplasias hematológicas1
Numerous developments are enabling ever more personalised leukemia treatments with lower toxicity Published on 19/06/2023 Recent studies have sought to demonstrate the effectiveness of new targeted therapies, such as FLT3 or menin inhibitors, and cellular therapy such as CAR-T in ever earlier scenarios
Bone marrow transplantation is still the only potential option of a cure for hematological tumors Published on 23/02/2023 Bone marrow donation, which may improve the patient's prognosis, does not pose any health risk for the donor nor does it require admission to the operating room
Improves the identification of genetic alterations in leukemia, allowing treatment to be personalized, improving its effectiveness Published on 20/06/2022 Depending on the type of leukemia, patients will have different genetic alterations or mutations that determine the progress of treatment
Hematologists face the challenge of incorporating Target Therapies into daily practice in the treatment of acute leukemia Published on 10/11/2021 Better understanding of cell tumor biology opens possibilities for targeted therapies in acute leukemia
Systemic mastocytosis, a disease of rare diagnosis, to be studied at the 10th Acute Leukemia Conference of MD Anderson Madrid – Hospiten Published on 27/09/2021 It will feature prominent speakers from different countries in America and Europe, as well as the intervention of professionals from the MD Anderson leukemia department in Houston
The incorporation of monoclonal antibodies to first line treatment of Multiple Myeloma improves survival rates Published on 07/09/2021 Autologous transplantation continues to be part of the standard treatment for newly diagnosed patients with no comorbidities, as well as the combination of chemotherapy with the anti-CD38 monoclonal antibody
MD Anderson Madrid – Hospiten participates in a protocol for bone marrow transplant patients to receive treatment at its center after the procedure Published on 25/02/2021 This allows patients with lymphoma or multiple myeloma who require a hematopoietic stem cell transplant to return to their center of origin to continue their own post-transplant care